Breast Cancer

Melissa Drew is an international keynote speaker and award-winning data and digital transformation consultant focusing on how AI technologies impact procurement and supply chain organizations. She has received numerous awards from Top 25 Global Consultants, Top Data Voice in North America, to Women Thought Leaders to follow in 2023. Melissa’s' priorities include running after twin teenagers, educating our next-generation workforce, and providing more opportunities for women's voices to be heard at conferences. A recent Cancer Warrior, Melissa was diagnosed with Stage 3 breast cancer in Jan 2022 and is currently cancer-free. A force to be reckoned with, she continues to break down barriers and share her knowledge and lesson's learned freely.

Breast Cancer Awareness

Professor Charles Coombes, Professor of Medical Oncology, Imperial College London. He is also Hon Consultant Medical Oncologist, Imperial College Healthcare Trust. From October 2010 Professor Coombes is Director of The Imperial CRUK Cancer Centre. He is also Chair of The Imperial Cancer Research (UK) Centre Steering Committee and Theme leader for Cancer, Imperial College London He is engaged in developing novel methods for prediction of response to endocrine therapy in breast cancer and also carrying out research aimed at understanding the mechanisms of resistance to endocrine therapy and development of novel anti-cancer drugs.

Molecular signals controlling aberrant growth of breast cancer cells with specific focus on the oestrogen receptor and allied cell signalling pathways

Dr Kyriakos Kalogerakos has completed his Degree in Medical School from Breast Unit of Metaxa Hospital, Greece

Breast Cancer Research

Indira Poola has completed her PhD in Biochemistry from Mysore University, Mysore, India and post-doctoral training at the University of Michigan and Cornell University in the USA. She served as a Professor in Biochemistry and Molecular Biology and Surgery at Howard University Medical School, Washington, D.C. USA for 17 years. She is currently President of Silbiotech, Inc., in Gaithersburg, MD, USA. She has won 27 grant awards from 9 funding agencies totaling over $8Million. She has published more than 40 papers in highly reputed journals and has served as an adhoc reviewer for 24 journals. She has served as an adhoc grant reviewer for 10 different agencies including NIH, DoD, NSF, EPA, and Komen for the Cure.

Receptors, Cancer biomarkers all areas of biochemistry

Dr. Wiseman brings more than 40 years of academic and clinical experience to Bria Cell Therapeutics Corp. As Co-Founder of Bria Cell, he is the inventor for most of the Company’s intellectual property and actively participates in its ongoing technology development. During his career, Dr. Wiseman has managed numerous clinical development teams and programs, with a focus in oncology, tumor immunology, vaccine development, and genetics. He was previously the principal investigator for immunotherapy treatment protocols at the St. Vincent Cancer Treatment Center and the Los Angeles Oncologic Institute. As the former Director of the Breast Cancer Basic Research Laboratory at the University of Texas M.D. Anderson Hospital in the 1970s, Dr. Wiseman was one of the pioneers of the field of cancer vaccine therapeutics. Dr. Wiseman is Clinical Professor of Medicine at the Division of Medical Oncology, Keck-USC School of Medicine, and previously was Acting Chief of the Division of Oncology/Hematology at White Memorial Medical Center.

Oncology, tumor immunology, vaccine development

Dr. El Hadji Seydou Mbaye was born in 1978 in Kaolack a region of Senegal. During 2008-2013, he earned his PhD in Biology and Human Pathologies with the collaboration of the International Agency for Research on Cancer / World Health Organization, (IARC/WHO), Lyon (France); He obtained a Master’s of Life and Health, Specialty Biology of microorganisms, Virology; a Master’s of Life and Health, option Immuno-physiopathology; a License of Biochemistry in Louis Pasteur University of Strasbourg (France); and a General Degree in Sciences and Technologies in University of METZ (France). He was certified Grade 10/10 by the Federation International of Gynecology Obstetric (FIGO), the Accreditation Council of Oncology in Europe (ACOE), and the Institute Catalan of Oncology (ICO). These credits were recognized as Physician’s Recognition Award (AMA PRA Category 1) by the American Medical Association. He was awarded as International Outstanding Scientist Awards 2020, Awarded as the Best Researcher Award 2021, by VDGOOD. He was certified, by the United Nations, by IARC/WHO. He has published 1 Book with a style of philosophical story. Author of the World Program against Cancer in Low and Middle Incomes Countries, he is lead author of more than 90 peer-reviewed research articles published in reputed journals. Dr. Mbaye is Editor-in-Chief of 4 journals, Editorial Board Member of 157 International Journals, and then he has Edited/Reviewed 270 peer-reviewed articles. He is member of Allied Academies, member of the World Society for Virology (WSV), member of World’s Leading Virologists Group: Facing to Covid-19, member of U.S. National Academies of Sciences, Engineering, and Medicine (NASEM): Societal Experts Action Network (SEAN), and also, member of BCNet International Working Group, IARC/WHO. Dr. MBAYE has formed for free, more than 250 Healthcare Professionals for the techniques of cervical cancer screening in Senegal. He has screened for free more than 2000 women for cervical cancer in Senegal. He appeared on local media, 2S TV, Leeral.net, Mbour TV, Sen TV and 7TV.

Oncology

Jose Russo has completed his MD University National of Cuyo, Mendoza in 1968. He is the director of The Irma H. Russo, MD Breast Cancer Research Laboratory and Breast Cancer TRDG Member. He has devoted over 40 years of lab to breast cancer research.

Breast Cancer and environmental factors Genomic Basis of Reproductive History in Breast Cancer Breast Cancer Therapy by Differentiation Gene Activation Estrogens and Breast Cancer Biomarkers of Breast Cancer Prevention Epigenetic Control of Estrogen Induced Cell Transformation

Dr. LuZhe Sun received his Ph.D. in Physiology from Rutgers University and UMDNJ-Robert Wood Johnson Medical School in 1990 and obtained his postdoctoral training in Baylor College of Medicine in the US. He is currently Professor, Dielmann Endowed Chair in Oncology, and Associate Director for Basic Research at his NCI-designated cancer center. Dr. Sun’s research is focused on investigating molecular mechanisms of tumorigenesis and metastasis, and novel experimental therapeutics in various models of carcinomas. His research has been supported with multi-million dollar grants from NIH, DOD, CPRIT, and other private foundations. He is an elected AAAS Fellow.

Oncology,Physiology, Medicine

Prof. Marion Kiechle is a Director and Chair of Klinik und Poliklinik fur Frauenheilkunde, Klinikum rechts der Isar, Technical University of Munich. She won the Award of the Bavarian State Orde (2015) and Award of the Federal Cross of Merit (2007). She is a Member of Leopoldina, National Academy of Sciences, Senator of the Technical University of Munich, Trustee of the Insitute of Advanced Studies of the Technical University of Munich.

Breast Cancer, Hereditary Breast and Ovarian Cancer, Gynecology, Oncology.

Dr. Hiltrud Brauch is a Deputy Head of Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Stuttgart, Head Breast Cancer Susceptibility and Pharmacogenomics. Prof Hiltrud Brauch came to the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (IKP) in 1999 after completing her training in Molecular Genetics of Cancer and Habilitation in the field of Molecular Pathology. She is a member of American Association of Cancer Research, American Society of Human Genetics.

Genetic Variation and Breast Cancer Risk Pharmacogenomics of Tamoxifen and other Endocrine Treatment Target Identification for Breast Cancer Therapy Clinical Sample Collections and Biobanking Pharmacogenomic Curriculum Fighting Breast Cancer

Dr. Roberto Murgo is the Head of the Senological Surgery Operative Unit of the San Giovanni Rotondo Relief House of Suffering Hospital. He has University Degree in Medicine and Surgery (July 1977) and Specialization in General Surgery (June 1982) at the University of Bari. He is the Author of over 90 scientific publications edited in print.

Medicine and Surgery

Specialist physician for gynecology and obstetrics, special operative gynecology, special gynecological oncology, drug therapy, senior mamma surgeon

Gynecological Oncology, Drug Therapy, Breast Cancer

She is a Professor at Karolinska Institutet , institutionen för onkologi-patologi •

Oncology